Cargando…
Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis
BACKGROUND: With an increasing indication spectrum of antiresorptive drugs, the medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy [MRONJ (BP)] is continuously gaining clinical relevance. Impaired osteoclast function, accompanied by altered cell morphology and expression...
Autores principales: | Wehrhan, Falk, Gross, Christian, Creutzburg, Kay, Amann, Kerstin, Ries, Jutta, Kesting, Marco, Geppert, Carol-Immanuel, Weber, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398259/ https://www.ncbi.nlm.nih.gov/pubmed/30832685 http://dx.doi.org/10.1186/s12967-019-1819-1 |
Ejemplares similares
-
Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis
por: Gross, Christian, et al.
Publicado: (2017) -
Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features
por: Wehrhan, Falk, et al.
Publicado: (2010) -
Clinical Management of Suppurative Osteomyelitis, Bisphosphonate-Related Osteonecrosis, and Osteoradionecrosis: Report of Three Cases and Review of the Literature
por: Guimarães, Eduardo Pereira, et al.
Publicado: (2013) -
Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFβ1-signaling and increased Galectin-3 expression: A histological study on biopsies
por: Wehrhan, Falk, et al.
Publicado: (2011) -
Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: An immunohistological study
por: Stockmann, Philipp, et al.
Publicado: (2011)